Thomas Masetto

Mr. Thomas Masetto

Sibioc
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
ADanne marie dupuy
anne marie dupuy
ABAnne Sophie Bargnoux
Anne Sophie Bargnoux
RLROMARIC LARCHER
ROMARIC LARCHER
AMAntoine Merindol
Antoine Merindol
Thomas MasettoThomas Masetto
Thomas Masetto
JCJean Paul Cristol
Jean Paul Cristol
We report the analytical performances of two particle-enhanced (PETIA) methods for measuring procalcitonin (PCT), the Diazyme PCT and the new DiaSys PCT assay, and their concordance of values with BRAHMS PCT Kryptor©. The total imprecisions onto two control levels and one serum pool were for DiaSys 5.42%, 3.3% and 7.53% and for Diazyme 10.7%, 2.9% and 13.23%, respectively. The limit of blank, limit of detection and limit of quantification were under the 0.25 cut-off for the two methods. The linearity in the lower range was acceptable for both methods. No significant effect on PCT determination was observed for DiaSys’ assay upon addition of interfering substances. With the Diazyme assay, significant effects were seen with rheumatoid factor (RF), lipid and hemoglobin. Correlation studies on 136 sera showed a good correlation between PCT measurements using DiaSys assay against the Kryptor system, while only a poor correlation was observed between the Diazyme assay, especially for low values. The novel PETIA PCT assay from DiaSys shows analytical performances acceptable for clinical use and the concordance with Kryptor method was fine at all clinical cut-offs. In contrast, despite comparable analytical performances, the Diazyme PETIA method exhibited a poor concordance with the Kryptor method.

17 August 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
JBJessica Brehm
Jessica Brehm
ASAlexander Spaeth
Alexander Spaeth
LDLars Dreßler
Lars Dreßler
Thomas MasettoThomas Masetto
Thomas Masetto
RDRainer Dannenberg
Rainer Dannenberg
MGMatthias Grimmler
Matthias Grimmler
Background: Since December 2019, SARS-CoV-2 has been keeping the world in suspense. Rapid tests, molecular diagnosis of acute infections, and vaccination campaigns with vaccines are building blocks of strategic pandemic control worldwide. For laboratory diagnostics, the quantification of the antibody titer of convalescents and vaccinated patients is thus increasingly coming to the fore.Methods: Here we present an evaluation on the comparability of five serological tests on a cohort of 13 patients with mild COVID-19 disease. Also participants who were vaccinated after recovery were included in this study. All common immune methods (ELISA, CLIA, PETIA) and SARS-CoV-2 specific antigens (N-, S1- and RBD-) were specifically tracked and directly compared for up to 455 days. The titer of recovered participants was also set to the degree of symptoms during infection and the occurrence of Long-COVID. In addition, relative comparability of different serological tests, all standardized to WHO, was set in reference to the neutralizing potential of the corresponding participants.Findings: The individual immune responses over 455 days after a mild SARS-CoV-2 infection remain stable, in contrast to vaccinated participants. All sero-tests reveal comparable performance and dynamics during the study and compared well to a surrogate neutralization test.Conclusion: The information presented here will help clinicians in the daily laboratory work in the selection and evaluation of different serological tests offered. The data also will support in respect of a sero-test-based neutralization cutoff.

1 July 2021 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Open access
PDF file
STSebastian-Alexander Tölke
Sebastian-Alexander Tölke
Thomas MasettoThomas Masetto
Thomas Masetto
MGMatthias Grimmler
Matthias Grimmler
LBLaura Bindila
Laura Bindila
KSKlaus Schneider
Klaus Schneider

25 July 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
ASAlexander Spaeth
Alexander Spaeth
Thomas MasettoThomas Masetto
Thomas Masetto
JBJessica Brehm
Jessica Brehm
LWLeoni Wey
Leoni Wey
CKChristian Kochem
Christian Kochem
MGMatthias Grimmler
Matthias Grimmler
In 2019, a novel coronavirus emerged in Wuhan in the province of Hubei, China. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quickly spread across the globe, causing the neoteric COVID-19 pandemic. SARS-CoV-2 is commonly transmitted by droplet infection and aerosols when coughing or sneezing, as well as high-risk exposures to infected individuals by face-to-face contact without protective gear. To date, a broad variety of techniques have emerged to assess and quantify the specific antibody response of a patient towards a SARS-CoV-2 infection. Here, we report the first comprehensive comparison of five different assay systems: Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Electro-Chemiluminescence Immunoassay (ECLIA), and a new Particle-Enhanced Turbidimetric Immunoassay (PETIA) for SARS-CoV-2. Furthermore, we also evaluated the suitability of N-, S1- and RBD-antigens for quantifying the SARS-CoV-2 specific immune response. Linearity and precision, overall sensitivity and specificity of the assays, stability of samples, and cross-reactivity of general viral responses, as well as common coronaviruses, were assessed. Moreover, the reactivity of all tests to seroconversion and different sample matrices was quantified. All five assays showed good overall agreement, with 76% and 87% similarity for negative and positive samples, respectively. In conclusion, all evaluated methods showed a high consistency of results and suitability for the robust quantification of the SARS-CoV-2-derived immune response.

6 September 2023 in Journal of Proteome Research
Verified
Journal Article
Closed access
STSebastian-Alexander Tölke
Sebastian-Alexander Tölke
Thomas MasettoThomas Masetto
Thomas Masetto
TRThomas Reuschel
Thomas Reuschel
MGMatthias Grimmler
Matthias Grimmler
LBLaura Bindila
Laura Bindila
KSKlaus Schneider
Klaus Schneider

8 January 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
LWLeoni Wey
Leoni Wey
Thomas MasettoThomas Masetto
Thomas Masetto
ASAlexander Spaeth
Alexander Spaeth
JBJessica Brehm
Jessica Brehm
CKChristian Kochem
Christian Kochem
MGMatthias Grimmler
Matthias Grimmler
Since SARS-CoV-2 emerged in December 2019 in Wuhan, the resulting pandemic has paralyzed the economic and cultural life of the world. Variants of concern (VOC) strongly increase pressure on public health systems. Rapid, easy-to-use, and cost-effective assays are essential to manage the pandemic. Here we present a bioinformatical approach for the fast and efficient design of two innovative serological Particle Enhanced Turbidimetric Immunoassays (PETIA) to quantify the SARS-CoV-2 immunoresponse. To confirm bioinformatical assumptions, an S-RBD- and a Nucleocapsid-based PETIA were produced. Sensitivity and specificity were compared for 95 patient samples using a BioMajesty™ fully automated analyzer. The S-RBD-based PETIA showed necessary specificity (98%) over the N protein-based PETIA (21%). Further, the reactivity and cross-reactivity of the RBD-based PETIA towards variant-derived antibodies of SARS-CoV-2 were assessed by a quenching inhibition test. The inhibition kinetics of the S-RBD variants Alpha, Beta, Delta, Gamma, Kappa, and Omicron were evaluated. In summary, we showed that specific and robust PETIA immunoassays can be rapidly designed and developed. The quantification of the SARS-CoV-2-related immunoresponse of variants (Alpha to Kappa) is possible using specific RBD assays. In contrast, Omicron revealed lower cross-reactivity (approx. 50%). To ensure the quantification of the Omicron variant, modified immunoassays appear to be necessary.